Dual GLP-1 / glucagon agonist being trialled for both obesity and MASH liver disease.
Typical dose range: 0.6–6 mg
Frequency: Weekly
Route: Subcutaneous
Half-life: ~7 days
Evidence level: Phase 3
Boehringer/Zealand candidate. The glucagon arm contributes notable hepatic fat reduction alongside the GLP-1 weight-loss effect.